Comparative Pharmacology
Head-to-head clinical analysis: BUTABARBITAL SODIUM versus BUTICAPS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTABARBITAL SODIUM versus BUTICAPS.
BUTABARBITAL SODIUM vs BUTICAPS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Depresses neuronal activity in the reticular activating system by enhancing GABA-A receptor-mediated chloride influx, increasing the duration of chloride channel opening and inhibiting excitatory neurotransmission at high doses.
Butalbital, a barbiturate, acts as a GABA-A receptor agonist, enhancing inhibitory neurotransmission in the CNS; acetaminophen inhibits cyclooxygenase (COX) activity and modulates endogenous cannabinoid receptors; caffeine is a non-selective adenosine receptor antagonist.
Sedative: 15-30 mg orally 3-4 times daily. Hypnotic: 50-100 mg orally at bedtime. Maximum single dose: 100 mg. Maximum daily dose: 300 mg. Route: oral, intramuscular, intravenous. For IM/IV: divide oral dose by 2.
500 mg orally every 8 hours.
None Documented
None Documented
Terminal elimination half-life: 30-50 hours; accumulates with repeated dosing, prolonged in hepatic impairment
3-5 hours (prolonged in renal impairment; dose adjustment required for CrCl <30 mL/min)
Renal: 50-70% as metabolites (hydroxylated and conjugated forms), 5-10% unchanged; fecal: minor (<5%)
Renal (90% as unchanged drug), biliary/fecal (10%)
Category C
Category C
Barbiturate
Barbiturate